Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: CareDx; Trovagene; Premaitha Health

NEW YORK (GenomeWeb) – CareDx announced this week that it has closed its acquisition of Allenex. The acquisition included a successful tender of 98.37 percent of Allenex shares as part of a public tender offer concluded in Sweden, the company said. CareDx will be able to buy out the remaining shares on a compulsory basis. The company said last week that Allenex shareholders representing about 98 percent of the company's shares had accepted CareDx's takeover offer.

Trovagene said this week that it has entered into an agreement with Stratose for in-network health plan access to Trovagene's suite of Precision Cancer Monitoring tests and services.

Premaitha Health this week reported 2015 revenues of approximately £2.5 million ($3.6 million). The sales — three-quarters of which were generated in the second half of the year — came primarily from four contracts augmented by a broadening portfolio of smaller customers using the company’s service laboratory, Premaitha said. Six more laboratory customers are in the installation phase and are expected to start contributing to sales during the first few months of 2016. As of March 31, the firm had cash on hand of £5.4 million.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.